Laurus Labs Limited — Call Transcript 2023

Jul 21, 2023

==> picture [452 x 75] intentionally omitted <==

July 21, 2023

To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Limited Phiroz Jeejeebhoy Towers, 25[th] Floor, Exchange Plaza, Dalal Street Bandra Kurla Complex, Bandra (East) Mumbai – 400001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS

Dear Sirs,

Sub: Q1 FY 24 Earnings conference call invite

Please find enclosed the Q1 FY 24 Earnings conference call invite for the call scheduled on July 27, 2023 at 05.00 PM (IST).

This is for your information and records.

Thanking you,

Yours sincerely, For Laurus Labs Limited VENKATESWAR Digitally signed by VENKATESWAR REDDY REDDY GOGIREDDY Date: 2023.07.21 09:57:47 GOGIREDDY +05'30' G. Venkateswar Reddy Company Secretary & Compliance Officer

Encl: As above

==> picture [452 x 43] intentionally omitted <==

LAURUS LABS LIMITED

==> picture [114 x 37] intentionally omitted <==

Laurus Labs Ltd Q1 FY2024 Results Conference Call to be hosted on Thursday, 27 July 2023 at 5:00pm IST

Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India, will organize a conference call for Investors and Analysts, on Thursday, 27 July 2023 at 5:00 PM IST. The conference call will be initiated with a brief management discussion on the Q1 FY2024 results, followed by an interactive Question & Answer session. The call will be hosted by Antique Stock Broking.

Details of the conference call are as follows:

For Diamond Pass please Copy this URL in your browser:

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9512515&linkSecurityString=330f63a5aa

Timing	5:00pm IST on July27, 2023
Conference dial-in
PrimaryNumber	+91 22 6280 1342
SecondaryNumber	+91 22 7115 8243_Available all over India_
Singapore	800101 2045
HongKong	800964 448
Japan	00531161110
USA	1 866 746 2133
UK	0 808 101 1573

==> picture [478 x 36] intentionally omitted <==

JULY 21, 2023

Press Release

==> picture [113 x 36] intentionally omitted <==

About Laurus | Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company with an aim to improve the quality of life for millions around the world. We have a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. We also offer integrated CMO and Contract Development and Manufacturing Organization (CDMO) services to Global Innovators from Clinical phase drug development to commercial manufacturing.

We are passionate about continuous technological advances for Smart and Green chemistry skills to driven efficiencies and sustainable manufacturing backed by proven regulatory inspection and quality foundation. Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. During FY2023 Laurus generated ₹ 6,041 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated “BBB” by leading MSCI ESG Ratings.

Corporate Identification No: L24239AP2005PLC047518

For more information about us, please visit http://www.lauruslabs.com or Contact particulars:

Investor Relations

Vivek Kumar Tel: +91 40 3980 4366 Email: investorrelations@lauruslabs.com

JULY 21, 2023

Press Release